Investments (Tables)

3 Months Ended

Mar. 31, 2023

Investments, Debt and Equity Securities [Abstract]

Schedule of Investments

The following is a summary of the Company’s investments at March 31, 2023 and December 31, 2022.

March 31, 2023
Securities Held		Acquisition Date		Shares Held		Price per Share		Value of Securities
Securities	Stock, options, and warrants		Various		Various		Various	$	6	1
Himalaya Technologies, Inc. (HMLA)	Series B, preferred stock		2021		150,000	$	0.08		270,000	2
HMLA	Warrants		2021		50,000,000	$	0.0018		89,826	2
Peer to Peer Network (PTOP)	Common stock		2019		210,000,000	$	0.0004		42,000	3
GenBio Inc.	Private company		2021 and 2022		50,000	$	1.00		65,000	4
								$	466,832

1 -	all investments are held at our third-party independent broker.
2 -	during 2021, the Company exchanged 1,000,000 shares of KANAB CORP. for 150,000 shares of Series B, preferred stock in HMLA. During 2021, a subsidiary of the Company also received 50,000,000 warrants with a five-year expiration and $.0001 exercise price of HMLA. The Company’s CEO is also the CEO of HMLA.
	The shares of series B preferred stock were valued at the fair value of HMLA as-if converted. The warrants were valued utilizing the Black-Scholes option pricing model.
3 -	based upon the quoted closing trading price.
4 -	based on cost method.

December 31, 2022
Securities Held		Acquisition Date		Shares Held		Price per Share		Value of Securities
Securities	Stock, options, and warrants		Various		Various		Various	$	6	1
Himalaya Technologies, Inc. (HMLA)	Series B, preferred stock and warrants		2021		150,000	$	0.08		12,000	2
Peer to Peer Network (PTOP)	Common stock		2019		210,000,000	$	0.0007		63,000	3
GenBio, Inc.	Private company		2021		25,000	$	1.00		65,000	4
								$	140,006

1 -	all investments are held at our third-party independent broker.
2 -	during 2021, the Company exchanged 1,000,000 shares of KANAB CORP. for 150,000 shares of Series B, preferred stock in HMLA. During 2021, a subsidiary of the Company also received 50,000,000 warrants with a five-year expiration and $.0001 exercise price of HMLA. The Company’s CEO is also the CEO of HMLA.
3 -	based upon the quoted closing trading price.
4 -	based on cost method.